作为 Cullin 家族的成员，Cullin2 (CUL2) 参与不同类型癌症的发生和扩散。然而，CUL2在人类癌症中的确切作用仍然很大程度上难以捉摸。在本研究中，应用各种数据库来观察CUL2的表达。采用 Kaplan-Meier 和 Spearman 相关分析来研究 CUL2 水平、患者预后和免疫细胞浸润之间的潜在联系。此外，在免疫治疗队列中研究了 CUL2 与免疫治疗疗效之间的关联。此外，利用人类蛋白质图谱（THPA）数据库观察细胞中CUL2的表达和分布。最后，通过临床组织标本和体外功能测定来验证CUL2在肝细胞癌（HCC）细胞中的表达及其对生物学功能的影响。虽然不同器官和细胞类型之间CUL2表达存在差异，但其显着上调存在于大多数肿瘤组织中。此外，CUL2基因突变常见于多种癌症，且突变率较低，且与部分癌症患者的预后、部分免疫调节因素、TMB、MSI、MMR基因、DNA甲基化等密切相关。此外，我们的结果发现，下调CUL2会抑制增殖和迁移能力。CUL2的表达对各种肿瘤的预后有影响，并且这种相关性特别值得注意，因为它与肿瘤内免疫细胞的浸润显着相关。 CUL2 是一种促进 HCC 进展的癌基因。

As a member of the Cullin family, Cullin2 (CUL2) is involved in the development and spread of different types of cancers. However, the precise role of CUL2 in human cancer remains largely elusive.In this study, various databases were applied to observe the CUL2 expression. Kaplan-Meier and Spearman correlation analyses were employed to investigate the potential links between CUL2 level, patient prognosis, and the infiltration of immune cells. In addition, the association between CUL2 and the efficacy of immunotherapy in an immunotherapy cohort was investigated. Moreover, the expression and distribution of CUL2 in cells were observed using the Human Protein Atlas (THPA) database. Finally, clinical tissue specimens and in vitro function assays were conducted to validate the expressions and effects of CUL2 on the biological functions in hepatocellular carcinoma (HCC) cells.While there are variations in CUL2 expression across different organs and cell types, it is notably upregulated in a majority of tumor tissues. In addition, CUL2 gene mutations are common in multiple cancers with low mutation rates and CUL2 is closely related to the prognosis of some cancer's patients, some immune regulatory factors, TMB, MSI, MMR genes, and DNA methylation. Further, our results found that downregulating CUL2 inhibits the proliferation, and migration abilities.The expression of CUL2 has an impact on the prognosis of various tumors, and this correlation is particularly noteworthy due to its significant association with the infiltration of immune cells within tumors. CUL2 was an oncogene contributing to the progression of HCC.